Mebiopharm Co., Ltd
HomeSitemapNotes for UsageInquiry{
Management Philosophy
Business Plan
Company Outline
Research & Development
Transferrin Products
Investor Relations
@ Mebiopharm Co., Ltd. What's New
May 25, 2016

Signed Agreement with Surgical Oncology in Nagoya University on "Development and Clinical Apply of Drug Delivery System on Nek2 siRNA Nucleic Acid Drug"

May 25, 2016

3 Years Government Grant, Nucleic Acid Liposome Project with Research Institute for Microbial Diseases in Osaka University got AMED Grant

Oct 20, 2015

Mebiopharm Announces Technology Evaluation Agreement with Merck to explore new tumor specific formulations

May 29, 2015

MBP-Y003 MOU executed
MOU execution with Fuan Pharmaceutical (Group) Co., Ltd. to license out the right to develop and commercialize for MBP-Y003, liposomal product attached transferrin as a ligand encapsulating Methotrexate, in China territory. USD 1,000,000 as an upfront payment

Jun 07, 2013

Announcement of Delisting and Arrangement of Shares

May 31, 2013

Venturing into the Japanese investment market with Mebiopharm Scrip Intelligence Online (May 30th)

Feb 12, 2013

Announcement of Developing Contrast Agent Using Nano-particle for Ultrasound Contrast

Oct 18, 2012

Presentation at 2nd APSTJ Meeting of DDS Focus Group on October 28, 2012 (Link in Japanese)

Sep 01, 2012

Presentation at 4th Annual Partnerships in Clinical Trials(Shanghai) on September 13, 2012

Jun 01, 2012

Starting a Clinical Study for Pancreatic Cancer

Mar 21, 2012

Presentation at Drug Discovery & Development Japan (Tokyo) on June 13, 2012

Feb 27, 2012

Consulting Agreement with Dr. Jean-Pierre Armand, M.D., MS.c, a world authority on cancer research field and a heavyweight in medical community in the world, for Mebiopharm's Phase 2 clinical trial in Europe.

Feb 20, 2012

Joint Venture Establishment in Sri Lanka

Feb 13, 2012

Presentation at Clinical Trials and Outsourcing (Shanghai)

Dec 07, 2011

Joint press conference on a joint venture in Sri Lanka (pdf in Japanese)

Dec 07, 2011

Announcement of establishing a joint venture in Sri Lanka (pdf in Japanese)

Nov 11, 2011

Lecture in 2nd Tokyo Venture Forum at Tokyo Stock Exchange

Oct 21, 2011

Presentation at JVCA (Japan Venture Capital Association)

Oct 12, 2011

Presentation about "Partnering with Japan for Clinical Trials" in Clinical Trials Asia Japan 2011 (Shanghai)

Sep 16, 2011

IR briefing session at Phillip Securities (HK) Ltd. Branch (Hong Kong, North Point)

Jul 15, 2011

Announcement of the listing on TOKYO AIM

Jul 11, 2011

Basic agreement about Technology Transfer between Chinese Pharma (in Japanese)

Jun 10, 2011

Investor Relations updated. (in Japanese)

Nov 10, 2010

Presentation by Dr. Jaffer Ajani (Prof. MDAnderson Cancer Center) about of MBP-426 Phase 2 study in PSWC 2010 in New Orleans (14-18 Nov.2010).

Sep 6, 2010

Article in NIKKEI newspaper about business collaboration with Chinese Pharma for licensing development right in Chinese market.

Aug 11, 2010

300million yen was invested through a private equity placement.

Aug 10, 2010

Presentation on September 29 about Clinical Development of Anticancer Drug in BioJapan2010.

Aug 1, 2010

"A study and development of evaluation methods of formulation and production to build up a scientific development strategy for drug formulation and production" by National Institute of Health Science that Mebiopharm takes part, is adopted as the governmental program "Health and Labour Sciences Research Grants / Research on Publicly Essential Drugs and Medical Devices".

Jul 15, 2010

Article about MBP-426 in Nikkei Sangyo Shinbun

Link (only in Japanese)

May 18, 2010

Presentation at the annual meeting of The Japan Society of Drug Delivery System

Link (only in Japanese)

Nov 18, 2009

Presentation on Phase 1b Study result of MBP-426 at the AACR-NCI-EORTC International Conference in Boston

Link to the poster

Sep 10, 2009

Presentation in Japan Biotech Forum in London 2009

Link to the website

May 30, 2009

MBP-426 promising Phase I result to be presented at ASCO 2009

Link to the poster

Feb 04, 2009

Phase II trial for 2nd line Gastric plus GE junction starts in U.S

Nikkei Biotech online



Click here to see past articles

Copyright© 2010 Mebiopharm Co., Ltd.@All Rights Reserved.